【ChiCTR2100047659】THE ROLE OF Ca 19-9, Ca 72-4, CEA AND CHOLESTEROL LEVELS IN PREDICTING MALIGNANCY IN GALLBLADDER POLYPS.
ChiCTR2100047659
结束
/
/
/
2021-06-21
/
/
Gallbladder polyps
THE ROLE OF Ca 19-9, Ca 72-4, CEA AND CHOLESTEROL LEVELS IN PREDICTING MALIGNANCY IN GALLBLADDER POLYPS.
THE ROLE OF Ca 19-9, Ca 72-4, CEA AND CHOLESTEROL LEVELS IN PREDICTING MALIGNANCY IN GALLBLADDER POLYPS.
01000
To determine a new algorithm in the diagnosis and treatment of gallbladder
连续入组
探索性研究/预试验
Ninety patients (MAN/WOMAN) diagnosed with gallbladder polyp by abdominal ultrasonography between December 2017 and November 2020 were included in the study
N/A
Writers
/
11
/
2020-11-18
2020-11-18
/
Ninety patients diagnosed with gallbladder polyp by abdominal ultrasonography between December 2017 and November 2020 were included in the study；
请登录查看Patients who were diagnosed with polyps in an external center, whose cholesterol levels and tumor markers were not tested before the operation, and who had undergone previous interventional procedures to the gallbladder were excluded from the study.；
请登录查看Nazmi OZER
01000
Nazmi OZER的其他临床试验
土耳其Adana city training and research hospital General surgery department的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04